Verified employee & interview reviews

Jubilant Pharmova Reviews

Noida, Uttar Pradesh

—/ 5

0 reviews

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, is an integrated global pharmaceutical company headquartered in Noida, Uttar Pradesh, India. Founded in 1978, the company operates across the pharmaceutical value chain, delivering specialized products and services to global markets, with a significant operational and commercial presence in North America, Europe, and India. The company underwent a strategic rebranding to Jubilant Pharmova in February 2021 following the demerger of its Life Science Ingredients business into a separate listed entity, Jubilant Ingrevia. The core operations of Jubilant Pharmova are structured around six distinct business segments: Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation (CDMO) Sterile Injectables, Generics, Contract Research Development and Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma vertical is the company's largest revenue contributor, specializing in nuclear medicine domain diagnostics and therapeutic agents. The company occupies a prominent position in the North American radiopharmaceutical market, operating the second-largest commercial radiopharmacy network in the United States with 46 radiopharmacies. Its key diagnostic offerings include MAA and DTPA, alongside its advanced cardiac imaging product, Ruby-Fill (Rubidium Elution System). In therapeutics, it stands as one of only three global manufacturers of Iodine-131. The Allergy Immunotherapy segment focuses on manufacturing and supplying allergenic extracts and specialized diagnostic skin-testing devices, holding a leading market position in the US, Canada, Europe, and Australia. Through its CDMO Sterile Injectables and CRDMO segments, Jubilant serves global biotech and pharma firms by offering contract manufacturing for sterile fill-and-finish injectables, liquids, ointments, creams, and drug discovery services. It maintains six manufacturing facilities globally located across India (including Bengaluru, Noida, Mysore, and Roorkee) and North America (Montreal, Canada; Spokane and Salisbury, USA). The Generics segment develops, manufactures, and markets solid dosage formulations across therapeutic areas like the central nervous system, cardiovascular system, and gastrointestinal treatments. Meanwhile, its proprietary drug discovery arm, Jubilant Therapeutics, focuses on advancing precision small-molecule therapeutics for oncology and autoimmune disorders. Financially, Jubilant Pharmova is publicly traded on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) under the ticker JUBLPHARMA. For the fiscal year ending March 31, 2026, the company reported trailing twelve-month revenue of approximately $930 million (with over 90% of revenues derived from the Americas and Europe) and a net income of $45.08 million. Led by Chairman Shyam S. Bhartia, Co-Chairman Hari S. Bhartia, and Managing Director Priyavrat Bhartia, the company employs over 5,500 people globally and continues to execute its long-term growth strategies under its Vision 2030 framework.